AKORN SIGNS LETTER OF INTENT WITH NATCO PHARMA TO DEVELOP AND SUPPLY TWO ORAL TABLET DRUG PRODUCTS

Akorn, Inc. (AMEX:AKN) today announced that it has signed a Letter of Intent with Natco Pharma Limited (NSE:NATCOPHARM) (MUMBAI:524816), located in Hyderabad, India, to develop and supply two ANDA oral tablet drug products for cancer patients suffering from nausea and vomiting. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Natco.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051219005224&newsLang=en)